Analyst Price Targets — ZNTL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 1:52 pm | — | Morgan Stanley | $5.00 | $4.28 | TheFly | Zentalis price target raised to $5 from $4 at Morgan Stanley |
| May 22, 2026 10:56 am | Andrew Fein | H.C. Wainwright | $10.00 | $4.14 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Zentalis Pharmaceuticals (ZNTL) |
| April 10, 2026 10:56 am | — | Guggenheim | $10.00 | $6.14 | TheFly | Zentalis price target raised to $10 from $6 at Guggenheim |
| November 11, 2025 9:50 am | Andrew Berens | Leerink Partners | $2.00 | $1.32 | StreetInsider | Zentalis Pharmaceuticals (ZNTL) PT Lowered to $2 at Leerink Partners |
| June 18, 2024 2:17 pm | Akash Tewari | Jefferies | $6.00 | $4.31 | TheFly | Zentalis downgraded to Hold from Buy at Jefferies |
| June 18, 2024 1:32 pm | Matthew Harrison | Morgan Stanley | $8.00 | $4.14 | StreetInsider | Morgan Stanley Downgrades Zentalis Pharmaceuticals (ZNTL) to Equalweight |
| June 18, 2024 11:46 am | Bradley Canino | Stifel Nicolaus | $10.00 | $5.39 | TheFly | Zentalis price target lowered to $10 from $32 at Stifel |
| June 18, 2024 10:45 am | Robert Driscoll | Wedbush | $4.00 | $5.70 | TheFly | Wedbush downgrades Zentalis to Underperform on unclear azeno path forward |
| May 7, 2024 4:31 pm | Bradley Canino | Stifel Nicolaus | $32.00 | $12.43 | StreetInsider | Zentalis Pharmaceuticals (ZNTL) PT Lowered to $32 at Stifel |
| November 14, 2022 9:32 am | — | Wedbush | $32.00 | $22.56 | Benzinga | Wedbush Maintains Outperform on Zentalis Pharmaceuticals, Lowers Price Target to $32 |
Latest News for ZNTL
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences:
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on September 1, 2026, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to…
Zentalis Pharmaceuticals, Inc. earns a cautious Buy rating, driven by azenosertib's potential in Cyclin E1-positive platinum-resistant ovarian cancer (PROC). DENALI and ASPENOVA trials target accelerated and full FDA approval, with pivotal data expected in H1 '27 as a major catalyst. Recent $93m capital raise extends cash runway into 2028, supporting regulatory milestones and mitigating near-term funding risk.
SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced that it has closed its previously announced underwritten public offering of…
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced the pricing of an underwritten public offering of 23,000,000 shares of its…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ZNTL.
U.S. House Trading
No House trades found for ZNTL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.